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IRISAbstract HIV is a leading cause of mortality in resource limited settings, and HIV associated med-
ical emergencies are common emergency department presentations in high-prevalence settings. HIV
attacks the body’s immune system, making infected individuals susceptible to severe infections of
multiple organ systems including the respiratory tract, ocular structures, and central nervous sys-
tem. HIV infected individuals also suffer from unique patterns of cardiac disease, gastrointestinal
disturbances, and haematologic and oncologic conditions. Anti-retroviral therapy itself is also asso-
ciated with numerous side effects, many of which can be life-threatening. Diagnosis and manage-
ment of HIV infected patients require knowledge of the disease’s pathology and the life
threatening complications associated with it. Part 2 of this article reviews haematologic/oncologic,
ocular, gastrointestinal, and treatment complications.
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IRISAbstract Le VIH est l’une des principales causes de mortalite´ dans les environnements caracte´rise´s
par des ressources limite´es, et les urgences me´dicales associe´es au VIH sont des motifs courants de
consultation dans les services d’urgence dans les zones a` forte pre´valence. Le VIH attaque le syste`me
immunitaire, rendant les individus infecte´s plus susceptibles de contracter de graves infections de
multiples organes, tels que les voies respiratoires, les structures oculaires et le syste`me nerveux cen-
tral. Les personnes se´ropositives souffrent e´galement de types de maladies cardiaques uniques, de
troubles gastro-intestinaux et de troubles he´matologiques et oncologiques. La the´rapie antire´trovi-
rale est elle-meˆme associe´e a` nombre d’effets secondaires, dont beaucoup peuvent s’ave´rer mortels.
Le diagnostic et la prise en charge des patients se´ropositifs ne´cessitent une bonne connaissance de la
pathologie de la maladie et des complications mortelles qui y sont associe´es. La deuxie`me partie de
cet article se penche sur les complications he´matologiques/oncologiques, oculaires, gastro-intesti-
nales et associe´es au traitement.
ª 2013 Production and hosting by Elsevier on behalf of African Federation for Emergency Medicine.African relevance
 HIV is a major cause of mortality in Sub-Saharan Africa.
 Patients with HIV associated emergencies often present to
African emergency departments with acute illnesses.
 Patients may be naive to their own infection, their CD4
count, or their speciﬁc HAART regimen, so clinicians
require a broad knowledge base to manage these
presentations.
 As HAART becomes more widely available across the con-
tinent, complications of treatment will become an increas-
ingly common issue.Introduction
Part one of this series discussed the pathophysiology of HIV
and associated respiratory, cardiac, psychiatric, and neuro-
logic complications. The paper highlighted a variety of
opportunistic infections (OI) and the challenges of tuberculosis
(TB) treatment. Part two continues from here and describes
haematologic/oncologic, ocular, gastrointestinal, and treat-
ment complications.
Haematologic/oncologic
HIV infected patients may present to the emergency centre
(EC) due to symptoms associated with haematologic and
oncologic diseases related to their HIV infection. While the
most common reason for presentation within this category is
severe anaemia, both thrombosis and symptoms related to
malignancies, either known or previously undiagnosed, also
occur with regularity.
Anaemia
Anaemia in HIV infected persons may be due to the infection
itself, anaemia of chronic disease associated with HIV
infection, bone marrow inﬁltration or suppression by HIV or
OIs (especially TB), or due to the medications used to treat
the infection and prevent OIs, particularly zidovudine (AZT)
and cotrimoxazole.1 While determination of the actual cause
of the anaemia is generally pursued outside of the EC, the ini-
tial laboratory tests should be sent from the EC, particularly ifthe patient’s anaemia warrants transfusion, as the diagnostic
workup must be postponed for at least three months after
transfusion to ensure accuracy. Important tests to be sent prior
to transfusion include full blood count, reticulocyte count, iron
studies, serum B12 and folate levels, and tests for haemolysis
including LDH, peripheral smear, haptoglobin and bilirubin
levels. Coagulation proﬁles should be sent in cases of bleeding
leading to anaemia, and creatinine and blood urea levels may
be useful in indicating renal dysfunction which may have led to
or contributed to chronic anaemia. Criteria for transfusion in
HIV patients are the same as those for uninfected patients, and
O negative blood should be used if blood matching the pa-
tient’s blood type is not available. Other cytopaenias may be
present with or without anaemia and may also be due to
HIV infection. Particular attention should be paid to patients
with thrombocytopenia, as both idiopathic thrombocytopenic
purpura and thrombotic thrombocytopenic purpura are more
common in HIV-infected persons, and have high rates of mor-
bidity and mortality; a peripheral smear should be sent imme-
diately to evaluate for schistocytes (RBC fragments) if either of
these conditions are suspected.2
Thrombosis (deep venous thrombosis/pulmonary embolism)
Although the mechanism is not yet well understood, it has
been demonstrated that HIV patients are four-times more
likely to develop deep venous thrombosis compared with unin-
fected persons of the same age and gender.3 HIV-infected pa-
tients are also 43% more likely to develop a pulmonary
embolism.4 Thrombotic potential has been found to increase
in direct relationship with opportunistic infections, malignan-
cies, AIDS-related nephropathy and auto-immune haemolytic
anaemia and in inverse relationship to the CD4 count.5 Con-
sideration of the interaction between warfarin and protease
inhibitors (PI) and non-nucleoside reverse transcriptase inhib-
itors (NNRTI) must be considered for HIV-infected patients
being treated for thrombosis.
AIDS-related malignancies
There are ﬁve AIDS-deﬁning malignancies, all of which have
been found to be largely virally-mediated: invasive cervical
cancer (HPV), Kaposi’s sarcoma (HHV-8), Burkitt’s
Lymphoma (EBV), Immunoblastic lymphoma (EBV and
HHV-8), and primary CNS lymphoma (EBV).6,7 Many other
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introduction of HAART therapy in most of Sub-Saharan Afri-
ca has presumably reduced the rates of many AIDS-related
malignancies, however, some reports indicate the rates of lym-
phoma have actually increased.2 Although HIV-related malig-
nancies are far less common than OIs in most of Sub-Saharan
Africa, signiﬁcant lymphadenopathy and weight loss without
respiratory symptoms, elevated LDH or unexplained cytopae-
nias, or ring-enhancing lesions on CT scan should prompt a
thorough evaluation of malignancy in addition to evaluation
and potential treatment for OIs.1 EC clinicians must always
include malignancy on their differential for any HIV-infected
person and ensure that patients who are discharged from the
EC receive appropriate follow up for symptoms concerning
for malignancy.
Ocular
The clinical presentation of an acute red eye in an HIV positive
patient should raise suspicions for two sight threatening infec-
tions: cytomegalovirus (CMV) retinitis and Varicella Zoster
Virus (VZV) ophthalmicus.
Cytomegalovirus
Chronic infection by CMV, also known as Human Herpes
virus 5, is common in the general population, but can lead
to life threatening infections when the immune system is com-
promised. CMV retinitis causes permanent damage to the ret-
ina and is associated with low CD4 count. It presents with
symptoms of ﬂoaters, light ﬂashes, and decreased visual acu-
ity.9 The infection can lead to retinal detachment and blind-
ness, and often spreads from one eye to the other when
diagnosis and therapy is delayed.10 The diagnosis is made by
history and fundoscopy, which reveals disc oedema and areas
of ischaemia and haemorrhage, often referred to as a ‘‘pizza
pie’’ appearance. In patients with atypical lesions or an unclear
diagnosis, DNA polymerase chain reaction (PCR) can be per-
formed on vitreous ﬂuid. Treatment involves systemic antivi-
rals (e.g., valganciclovir or ganciclovir) and ophthalmologic
consultation for possible intravitreal antiviral injection or
intraocular antiviral implants (ganciclovir) and retinal repair.
HAART should be initiated after commencing antiviral treat-
ment. In resource limited settings with poor access to ophthal-
mologists, primary care providers can be trained to detect
CMV and perform intravitreal injections.11 Immune recovery
with HAART is critical to managing ocular CMV, although
it can initially worsen inﬂammation and lead to immune recov-
ery uveitis.12,10
Varicella zoster ophthalmicus
VZV, also known as Human Herpes Virus 3, is the causative
agent of chickenpox (varicella), after which it remains dormant
in the peripheral nervous system. Later in life, it can cause a
viral reactivation syndrome along a particular dermatome
commonly referred to as zoster or shingles. These episodes
can be precipitated by physiologic stress or an immunocom-
promised state, and are sometimes preceded by a viral syn-
drome prodrome. VZV ophthalmicus occurs when the
reactivation involves the nasociliary branch of the ﬁrst (oph-
thalmic) division of the ﬁfth cranial (trigeminal) nerve, andaccounts for 10–25% of all zoster cases.13 The condition
causes lesions on the cornea, anterior uveitis, and eventually
corneal scarring and retinal necrosis. Long-term complications
occur in about 50% of patients with this condition and include
chronic pain and blindness.14 The disease should be suspected
in all patients presenting with acute red eye with or without
shingles of the face, especially when associated with Hutchin-
son’s sign: vesicular rash on the tip of the nose (also innervated
by the nasociliary branch). HIV infection and Hutchinson’s
sign are each associated with higher rates of post infection
ocular complications.15 Diagnosis is conﬁrmed by the
visualization of dentritic lesions on the cornea when viewed
with ﬂuorescein stain. Treatment includes analgesia, eye lubri-
cation, and immediate initiation of systemic antivirals (e.g.,
acyclovir). Patients should be referred for urgent ophthalmo-
logic evaluation where available.
Gastrointestinal
Diarrhoea and dysphagia are common gastrointestinal tract
symptoms of HIV positive patients presenting to ECs.16
Abdominal pain in the setting of a low CD4 count or new anti-
retroviral regimens should raise suspicion for colitis, enteritis,
hepatitis, TB abdomen, or pancreatitis.
Causes of diarrhoea include HAART side effects (e.g., pro-
tease inhibitors), common bacterial pathogenic strains, Myco-
bacterium avium-intracellulare, Cryptosporidia, Isospora, and
CMV.17 A deﬁnitive diagnosis may depend on stool micros-
copy and culture results or colonoscopy with biopsy where
available. Special stains may be required to identify certain
diarrheal pathogens on microscopy. Treatment involves rehy-
dration and supportive care. In cases where acute bacterial
diarrhoea is suspected, associated with fever, abdominal pain,
and bloody stool, treatment should include a third generation
cephalosporin or a ﬂuoroquinolone. For chronic diarrhoea,
empiric antibiotics, e.g., metronidazole or a sulphonamide,
can be considered depending on the local prevalence of causa-
tive pathogens. HAART initiation can lead to the resolution of
certain types of HIV-associated chronic diarrhoea.
Oesophageal symptoms, retrosternal odynophagia, and
dysphagia are commonly associated with candidal esophagitis,
a common AIDS deﬁning illness. CMV, HSV, and aphthous
ulcers can also cause similar symptoms, associated with ulcer-
ating lesions along the oesophagus, and should be considered
if the disease does not respond to ﬂuconazole therapy. Endos-
copy and barium swallow evaluation may also be needed to
rule out oesophageal malignancies like Kaposi’s sarcoma,
non-Hodgkin’s lymphoma, and adenocarcinoma.18
Complications of treatment
The devastating course of HIV infection can only be halted
with effective HAART. Various classes of HAART have
emerged targeting multiple enzymes, proteins and receptors
integral to the HIV life cycle. In resource-limited settings,
HAART regimens are commonly composed of two nucleoside
reverse transcriptase inhibitors (NRTIs) paired with a non-
nucleoside reverse transcriptase inhibitor (NNRTI) (1st line)
or a protease inhibitor (PI) (2nd line).
Major short-term complications of HAART are related to
the drug class and particular drug itself. Table 1 outlines com-
mon HAART abbreviations and adverse drug events. Adverse
Table 1 Common anti-retrovirals by class and toxicities.21,26,28,29
Anti-retrovirals Abbreviation Severe adverse events
NRTIs
Abacavir ABC Hypersensitivity reaction
Didanosine ddI Lactic acidosis, Hepatitis, Pancreatitis
Emtricitabine or Lamivudine FTC 3TC Hepatitis B exacerbation on discontinuation 3TC: red cell aplasia
Stavudine D4T Lactic acidosis, Hepatitis, Pancreatitis, Neuromuscular weakness
Tenofovir TDF Renal failure, Hepatitis B exacerbation upon discontinuation
Zidovudine AZT Anaemia, Neutropenia, Lactic acidosis
NNRTIs
Efavirenz EFV Rash, Stevens-Johnson Syndrome, Hepatotoxicity, Neuropsychiatric
Nevirapine NVP Rash, Stevens–Johnson syndrome, Hypersensitivity reaction, Hepatotoxicity
Etravirine ETF Rash
PIs*
Ritonavir RTV or r
Atazanavir ATV 1st degree AV Block, Nephrolithiasis, Unconjugated Hyperbilirubinaemia
Darunavir DRV Stevens–Johnson syndrome, Erythema multiforme, Hepatotoxicity
Fosamprenavir FPV
Indinavir IDV Nephrolithiasis
Lopinavir/r LPV/r
Saquinavir SQV
Tipranavir TPV Cerebral haemorrhage, Hepatotoxicity
Integrase Inhibitor
Raltegravir RAL Rash
*All PIs can cause hypertriglyceridaemia and pancreatitis. All boosted PIs have the potential to cause conduction delays.
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36% of patients receiving HAART often occurring within
the ﬁrst 6 months.19 A few HAART side effects warrant
prompt diagnosis to avoid unnecessary morbidity and
mortality.
Hepatotoxicity
Though the patterns and deﬁnitions of hepato-toxity differ, se-
vere elevations in ALT (>5x upper limits of normal) are seen
in up to 14% of individuals on HAART and are further com-
plicated with concurrent HBV or HCV infection.20 The spec-
trum of disease can range from asymptomatic elevations in
LFTS to fulminant liver failure. HAART most associated with
hepatotoxicity are 1st generation NNRTIs (NVP, EFV),
NRTIs (ABC, d4T, ddI), PIs (DRV, LPV, ATV, etc.) though
almost all antiretroviral agents carry the potential to cause
hepatotoxicity in varying degrees. In resource-limited settings,
hepatotoxicity is most commonly caused by the use of NVP.
NVP induced hepatotoxicity can result in symptomatic hepati-
tis in 2.5–11% of recipients with 50% of cases presenting with
a hypersensitivity reaction.21 Severe liver toxicity with subse-
quent liver failure has been reported. Atazanavir can cause
an indirect hyperbilirubinaemia though it rarely leads to drug
discontinuation. D4T and ddI can cause steatohepatitis.
Nephrotoxicity
Renal failure, whether acute or chronic, has various aetiologies
in the context of HIV. Though the exact mechanism is unclear,
HIV-associated nephropathy (HIVAN) has been frequently
described in patients with AIDS, most commonly those not
receiving HAART. Characteristics of HIVAN include nephri-
tic range proteinuria, large echogenic kidneys on ultrasoundand detectable plasma HIV. HAART is the mainstay of treat-
ment. However, HAART itself can also have nephrotoxic
effects.
The majority of nephrotoxicity has been associated with
IDV, TDF and more recently, ATV. Those with prior renal
impairment are generally at higher risk. Given widespread
use, TDF related nephrotoxicity will be commonly encoun-
tered in clinical practice. TDF can cause damage to the renal
tubules and glomerulus causing a diversity of injury from Fan-
coni’s syndrome to acute renal failure. IDV induced nephro-
toxicity can be caused by nephrolithiasis, tubulointerstitial
nephritis or acute renal failure; nephrolithiasis can also be
caused by ATV.21
Though only a few ARVs can directly cause nephrotoxicity,
many more require renal dosing in patients with diminished
GFR. A decrease in renal function should be monitored care-
fully with prompt evaluation of aetiology and renal dosing of
medications where applicable.
Pancreatitis
Pancreatitis is a rare complication of the NRTIs d4T and ddI
(especially when used in combination) and all PIs. NRTI-
associated pancreatitis can occur alone or in conjunction with
lactic acidosis.22 Though ARVs are most commonly
implicated, administration of cotrimoxazole has also been
associated with pancreatitis, albeit in rare cases.23 Patients
commonly present with symptoms of epigastric abdominal
pain, nausea, vomiting and inability to tolerate food. Lipase
is commonly elevated. Amylase is non-speciﬁc and elevations
can also be caused by non-pancreatic mechanisms. In
addition to prompt discontinuation of HAART, treatment
includes supportive care with intravenous ﬂuids, nothing by
mouth and pain control.24
Table 2 Criteria for lactic acidosis.26
Lactate > 2 mmol/L
pH< 7.35
HCO3 < 20 mmol/L
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Lactic acidosis is a known side effect of NRTIs, especially with
d4T and ddi though others (AZT, 3TC = TDF) are capable to
a lesser degree.25 In resource-limited settings where d4T is still
widely used, lactic acidosis should be suspected with non-
speciﬁc symptoms which can include abdominal pain, nausea,
vomiting, fatigue, dyspnoea, and recent weight loss. Symptoms
may occur months to years after starting NRTIs. The criteria
used to diagnose lactic acidosis are shown in Table 2. If ABG
and measurement of lactate are not possible, an anion gap may
be suggestive in the right clinical context. Lab ﬁndings of in-
creased CK, LDH, lipase and LFTs are supportive of the diag-
nosis. Clinicians must maintain a high index of suspicion for
the condition as mortality can be as high as 60%.25,20 Progres-
sion to liver failure can also occur. Since signs and symptoms
can mimic clinical features of sepsis, empiric management may
also include obtaining cultures and administering broad spec-
trum antibiotics. The mainstay of treatment of lactic acidosis is
discontinuation of all HAART and supportive care with
aggressive ﬂuid resuscitation. Evidence is limited for the rou-
tine use of sodium bicarbonate or vitamin co-factors. Upon
clinical resolution, HAART can be reinitiated with ABC or
TDF in combination with 3TC or FTC; D4T, DDI, and
AZT should be avoided.24
Anaemia
The NRTI, AZT, is known to cause macrocytic anaemia, usu-
ally developing in the ﬁrst 6 months of treatment.24 In one
study, up to 20% of patients on AZT-containing regimens
developed anaemia though lower rates have been reported else-
where.24 Signs and symptoms of symptomatic anaemia include
pallor, fatigue, generalized weakness, orthostatic hypotension,
shortness of breath and chest pain. Symptomatic patients
should be transfused. AZT should be discontinued and chan-
ged to an alternate NRTI.
Hypersensitivity reactions
Abacavir hypersensitivity reaction (AHR) is a systemic re-
sponse to the NRTI, ABC. Though the HLA B5701 allele is
associated with AHR, gene testing is not commonly performed
in resource-limited settings. Moreover, the prevalence of
B5701 appears to be <1% in the African population so it rep-
resents a rare complication.26 Of those with AHR, up to 70%
of patients will report a rash with multi-organ involvement.2426
Symptoms usually develop within the ﬁrst 6 weeks and can
range from fever, malaise, nausea, vomiting, abdominal pain,
cough, shortness of breath or other constitutional symptoms.
As AHR can present as a viral illness, a high index of clinical
suspicion should be maintained. Labs can reveal elevated
LFTs and CPK, and low lymphocytes. Most initial reactions
can be addressed with supportive care and by discontinuingthe offending agent. However, mortality is higher with re-
exposure and patients should be instructed to never use the
drug again.24 ABC should be changed to an alternate NRTI.
The NNRTI, nevirapine (NVP), is also associated with a
systemic hypersensitivity reaction. Antiretroviral therapy naı¨ve
patients with pre-initiation CD4 > 250 cells/mm3 in women
and >400 cells/mm3 in men are at higher risk. NVP-related
hypersensitivity can be associated with constitutional symp-
toms, fever, rash, and hepatitis.24 Rash is among the most
common side effects by users of NVP. Steven’s Johnson’s
Syndrome (SJS) and Toxic epidermal necrolysis (TEN) are
potentially lethal dermatologic toxicities manifested by blis-
ters, bullae, sloughing of the skin and/or mucus membrane
involvement. Mainstay of treatment depends on cessation of
NVP, and management as burns with supportive care.
Immune reconstitution inﬂammatory syndrome
HAART initiation promptly leads to a fall in HIV viral load
and higher CD4 cell numbers and function. This initial immune
response can lead to paradoxical clinical worsening referred to
as IRIS and has been noted in 10–32% of patients initiating
HAART.27 The underlying pathogenesis appears to be a dys-
regulated immune response to antigens and/or pathogens.26
IRIS can present as a ‘‘paradoxical’’ exacerbation of a known,
pre-existing OI or ‘‘unmasking’’ of a newly diagnosed OI.
Though there is no universal consensus on the deﬁnition of
IRIS, any clinical worsening not attributable to drug toxicity
should raise suspicion. IRIS is frequently attributed to myco-
bacterium infections and fungal infections, particularly tuber-
culosis and cryptococcus respectively though any pathogen
can be implicated. IRIS involving the CNS can be life threaten-
ing and fatal. In addition to treating the underlying OI, IRIS
therapy consists of NSAIDs and in severe cases, steroids.26
HAART can usually be safely continued with rare exceptions.27Conclusion
The prevalence of speciﬁc HIV related presentations to acute
care facilities is not well known. HIV infected patients can
present with diseases common in the uninfected population,
and they can present with a variety of HIV associated condi-
tions. The situation is complicated by the fact that many of
these patients may not know their HIV status. Subacute or
chronic conditions associated with HIV infection, and not
diagnosed or managed in a timely fashion by primary care ser-
vices, can progress to life threatening situations. An HIV asso-
ciated emergency should therefore be a strong consideration
for any critically ill patient, especially in high prevalence
regions.
Clinicians working in ECs should have a broad knowledge
of HIV, its effects on host immune systems, and common HIV
associated diseases. In high prevalence regions, bedside rapid
HIV testing can aid in diagnosis and management of critically
ill patients.Acknowledgment
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